WO2007137135A3 - Analogues de roténone, méthode de préparation et d'utilisation - Google Patents

Analogues de roténone, méthode de préparation et d'utilisation Download PDF

Info

Publication number
WO2007137135A3
WO2007137135A3 PCT/US2007/069178 US2007069178W WO2007137135A3 WO 2007137135 A3 WO2007137135 A3 WO 2007137135A3 US 2007069178 W US2007069178 W US 2007069178W WO 2007137135 A3 WO2007137135 A3 WO 2007137135A3
Authority
WO
WIPO (PCT)
Prior art keywords
rotenone
analogs
preparation
present
tracers
Prior art date
Application number
PCT/US2007/069178
Other languages
English (en)
Other versions
WO2007137135A2 (fr
Inventor
James P O'neil
Brocklin Henry F Van
Nandanan Erathodiyil
Andrew R Gibbs
Original Assignee
Univ California
James P O'neil
Brocklin Henry F Van
Nandanan Erathodiyil
Andrew R Gibbs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, James P O'neil, Brocklin Henry F Van, Nandanan Erathodiyil, Andrew R Gibbs filed Critical Univ California
Publication of WO2007137135A2 publication Critical patent/WO2007137135A2/fr
Publication of WO2007137135A3 publication Critical patent/WO2007137135A3/fr
Priority to US12/273,509 priority Critical patent/US8551448B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des analogues de roténone et des méthodes de fabrication et d'utilisation de ceux-ci. Lesdits analogues de roténone sont marqués par des isotopes monophotoniques et d'émission de positons et sont utiles dans des applications d'imagerie clinique en tant que traceurs pour mesurer la circulation sanguine cardiaque et détecter des régions d'ischémie.
PCT/US2007/069178 2006-05-18 2007-05-17 Analogues de roténone, méthode de préparation et d'utilisation WO2007137135A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/273,509 US8551448B2 (en) 2006-05-18 2008-11-18 Rotanone analogs: method of preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80133206P 2006-05-18 2006-05-18
US60/801,332 2006-05-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/273,509 Continuation US8551448B2 (en) 2006-05-18 2008-11-18 Rotanone analogs: method of preparation and use

Publications (2)

Publication Number Publication Date
WO2007137135A2 WO2007137135A2 (fr) 2007-11-29
WO2007137135A3 true WO2007137135A3 (fr) 2008-04-03

Family

ID=38724021

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/069178 WO2007137135A2 (fr) 2006-05-18 2007-05-17 Analogues de roténone, méthode de préparation et d'utilisation

Country Status (1)

Country Link
WO (1) WO2007137135A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102336764B (zh) * 2011-06-21 2013-10-30 兰州大学 自旋标记鱼藤酮肟酯及其制备方法和用途
CA2839351C (fr) * 2011-07-13 2015-11-24 Nordion (Canada) Inc. Derives de rotenone radio-marques et leur utilisation en imagerie spect
KR101422189B1 (ko) 2012-10-24 2014-07-22 한국원자력연구원 신규한 로테논 유도체 및 이를 유효성분으로 함유하는 비만 예방 및 치료용 약학적 조성물
CN103044440B (zh) * 2012-12-31 2015-11-18 深圳市华农生物工程有限公司 一种鱼藤酮临界萃取方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086476A1 (fr) * 2002-04-08 2003-10-23 Biostream, Inc. Derives de rotenone a marquage au technetium, et procedes d'utilisation correspondants
US20050192458A1 (en) * 2002-04-30 2005-09-01 Goodman Mark M. Tumor imaging compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003086476A1 (fr) * 2002-04-08 2003-10-23 Biostream, Inc. Derives de rotenone a marquage au technetium, et procedes d'utilisation correspondants
US20050192458A1 (en) * 2002-04-30 2005-09-01 Goodman Mark M. Tumor imaging compounds

Also Published As

Publication number Publication date
WO2007137135A2 (fr) 2007-11-29

Similar Documents

Publication Publication Date Title
WO2008010227A3 (fr) protocoles d'imagerie
WO2007010534A3 (fr) Protocoles d'imagerie
WO2008033561A3 (fr) Dérivés cyclopeptidiques dérivés de la chimie clic utilisés en tant qu'agents d'imagerie des intégrines
WO2008128049A3 (fr) Procédés d'administration de la tétrahydrobioptérine, compositions associées et procédés de mesure
WO2008098112A3 (fr) Procédé d'imagerie de tomographie par émission de positrons
WO2015073746A3 (fr) Marquage de protéines au 18f, faisant appel à des sortases
CL2013003262A1 (es) Compuestos derivados de 1,3-oxazinas, con actividad inhibidora de bace 1 y/o bace2; composición farmacéutica que los comprende; procedimiento de preparación; uso en el tratamiento de la enfermedad de alzheimer, diabetes, trombosis arterial, cáncer, infarto al miocardio, entre otras patologías.
NZ606466A (en) Peptide radiotracer compositions
WO2011015602A3 (fr) Biomarqueurs du cancer du poumon
WO2009052970A3 (fr) Composés destinés à être utilisés dans le cadre d'imagerie, de diagnostic et/ou de traitement de maladies du système nerveux central ou de tumeurs
WO2007137135A3 (fr) Analogues de roténone, méthode de préparation et d'utilisation
WO2009134405A3 (fr) Nouveaux agents d’imagerie tep basés sur un substrat
WO2009018175A3 (fr) Azapeptides cycliques en tant que marqueurs d'intégrine
WO2009045535A3 (fr) Derive de dasatinib marque au fluor 18 et utilisations associees
TN2016000083A1 (en) Methods and tools relating to the administration of contrast medium
WO2008133730A3 (fr) Analogues de roténone marqués
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
WO2012040138A3 (fr) Nouveau radiotraceur
MX340487B (es) Compuestos para usarse en la formacion de imagenes, diagnostico y/o tratamiento de enfermedades del sistema nervioso central.
WO2009140743A3 (fr) Imagerie du sang
WO2008151003A3 (fr) Nouveau dérivé de rhodamine marqué au fluor 18 pour imagerie de perfusion myocardique avec homographie par émission de positron
WO2011159741A3 (fr) Immunogènes spécifiques de tétranor-pgem/pgam, anticorps, traceurs, kits d'essai et procédés pour fabriquer ceux-ci
WO2011109285A3 (fr) Marqueur de pronostic pour vascularité cryoglobulinémique et malignités à cellules b chez les patients infectés par le vhc
NO20092813L (no) Radiomerking via fluorinering av aziridiner
CL2007002576A1 (es) Compuesto peptidico; compuesto peptidico con al menos un aptamero; conjunto de elementos para preparar preparacion radiofarmaceutica; metodos para producir dichos compuestos; uso de dichos compuestos para el diagnostico y/o terapia de enfermedad prol

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07783894

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07783894

Country of ref document: EP

Kind code of ref document: A2